Our data were obtained by searching PubMed and EMBASE databases. DOIs and PMIDs of each trial included in this meta-analysis are included in the references.

Introduction {#sec005}
============

Hepatic fibrosis (HF) results from the healing response to chronic hepatic disease \[[@pone.0147789.ref001]--[@pone.0147789.ref003]\]. It is associated with a progressive increase in the accumulation of extracellular matrix that may influence both the diffusion of water molecules and microcirculation \[[@pone.0147789.ref004]\]. As a result, some life-threatening complications such as cirrhosis, portal hypertension, hepatocellular carcinoma (HCC), and 1iver failure can develop in patients with HF \[[@pone.0147789.ref005]--[@pone.0147789.ref007]\]. The diagnosis of HF was confirmed by histopathologic examination and the stages of HF were scored using the METAVIR classification system. If HF is diagnosed at an early stage (F1-2, defined as non-advanced HF), appropriate intervention and treatment can prevent its progression. However, stage F3-4 can be difficult to reverse and therefore is defined as advanced HF \[[@pone.0147789.ref008],[@pone.0147789.ref009]\]. It is widely accepted that patients without HF or with early HF have a low risk of liver failure, while those in stages higher than F2 (i.e. significant HF) have a higher risk of liver failure, along with a higher risk of cirrhosis in the future \[[@pone.0147789.ref010]\]. Therefore, the early and accurate diagnosis of HF in patients with chronic hepatic disease is critical and necessary.

To date, liver biopsy is only a gold standard when performed correctly (enough portal triads, good condition after histological processing) and assessed by experienced pathologists specialized in liver pathology; in addition, it has some other limitations including sampling error, the rare possibility of patient mortality or morbidity, and interobserver or intraobserver variability \[[@pone.0147789.ref001],[@pone.0147789.ref011],[@pone.0147789.ref012]\]. Therefore, there has been an increasing need for an alternative noninvasive tool for HF diagnosis.

Diffusion-weighted magnetic resonance imaging (DWI) is one such promising noninvasive technique, but it is limited in its ability to evaluate hepatic diffusion and detect the early stages of fibrosis when perfusion is not significantly altered \[[@pone.0147789.ref002]\]. The lower apparent diffusion coefficient (ADC) values in advanced stages of HF is mainly due to decreased perfusion rather than decreased extravascular diffusion \[[@pone.0147789.ref013]\]. Meanwhile, other non-invasive methods have been developed for the detection of HF, such as ultrasonographic diagnosis, transient sonoelastography, computed tomography (CT), dynamic contrast-enhanced (DCE) MRI, and MR elastography \[[@pone.0147789.ref014]--[@pone.0147789.ref018]\]. Intravoxel incoherent motion (IVIM) MRI is a method based on DWI, which allows for the assessment of pure molecular diffusion and microcirculation separately \[[@pone.0147789.ref019],[@pone.0147789.ref020]\]. Classically, IVIM acquisitions are respiratory triggered and the IVIM DW imaging sequence is based on a single-shot DW spin-echotype echo- planar imaging sequence, with multiple b values. According to IVIM theory, signal attenuation as a function of multiple b values encompassing both low b values (\< 200 sec/mm^2^) and high b values (\> 200 sec/mm^2^) could be expressed by a biexponential, instead of a mono-exponential equation with three parameters: perfusion-related diffusion (D\*), perfusion fraction (*f*), and pure molecular diffusion (D) \[[@pone.0147789.ref021]\]. D\* and *f* are related to blood perfusion, and D is related to water diffusion. Consequently, IVIM imaging is more informative than DWI. IVIM MR imaging has been used to detect tumors \[[@pone.0147789.ref022]--[@pone.0147789.ref026]\], chronic brain ischemia \[[@pone.0147789.ref027]\], renal perfusion \[[@pone.0147789.ref028]\], and hepatic focal lesions \[[@pone.0147789.ref029]\]. In this meta-analysis, we investigated the value of IVIM MR imaging in the staging of HF.

However, little is known about the value of IVIM MR imaging for the staging of HF and the existing findings are controversial according to the previous studies \[[@pone.0147789.ref001],[@pone.0147789.ref002],[@pone.0147789.ref004],[@pone.0147789.ref005],[@pone.0147789.ref019]\]. Therefore, we performed this meta-analysis to determine the potential value of IVIM imaging in the staging of HF.

Materials and Methods {#sec006}
=====================

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ([S1 Checklist](#pone.0147789.s001){ref-type="supplementary-material"}). Since this was a meta-analysis that did not involve identifiable patient information, no particular ethical considerations were required.

Data sources and searches {#sec007}
-------------------------

We performed a comprehensive literature search to identify articles investigating the value of IVIM MR imaging in the diagnosis and staging of HF. The PubMed and EMBASE databases were searched from the date of their inception to 31 July, 2015, without language restriction. Medical subject headings and keyword searches in combination included the terms 'intravoxel incoherent motion', 'ivim', 'intravoxel incoherent motion diffusion weighted imaging', 'ivim dwi', 'hepatic fibrosis', 'hepatic fibrosis', "LF", "HF", and 'humans'.

Study selection {#sec008}
---------------

Two investigators independently reviewed the title and abstract of all studies to identify those of interest. The online publications identified from the preliminary selection were then reviewed in full text to assess if the studies met the following inclusion criteria:

1.  Participants: patients with pathologically staged HF or healthy volunteers without history of chronic hepatic disease or significant alcohol intake. All of them underwent IVIM-diffusion weighted magnetic resonance imaging (IVIM-DWI).

2.  Comparison: IVIM-derived parameters (including D\*, *f*, and D) and apparent diffusion coefficient (ADC) were compared between different stages of HF (i.e. F0, F1, F2, F3, and F4).

3.  Type of study: Original research.

The exclusion criteria were as follows: 1) Duplicate or irrelevant publications; 2) low quality, that is, QUADAS score \< 9; 3) Insufficient data for extraction and analysis, for instance, comparison only between F4 and F0.

The final inclusion of studies was based on the agreement of both investigators.

Data extraction and quality assessment {#sec009}
--------------------------------------

Two authors extracted data independently. Disagreements were solved by discussion and consultation with a third author. For accuracy analyses, we extracted the following data for every study: author; year of publication; baseline information about the patients (e.g., age, gender); sample size; MR scanner; criteria for staging HF; study design; and diagnosis of hepatic fibrosis, etc.

Although we had insufficient data for performing an assessment of diagnostic accuracy, we still used the QUADAS tool to assess the quality of included studies. This evidence-based tool includes 14 quality items, presented as questions and scored as 'yes', 'no', or 'unclear'. The quality assessment score can range from 0 to 14. One study with a score \< 9 was deemed to be of low quality.

Data synthesis and analysis {#sec010}
---------------------------

Since different stages of HF had been compared in different studies, we had to calculate the pooled mean and standard deviation (SD) of IVIM parameters and ADC. The following equations were used: $$M = \frac{N_{1}M_{1} + N_{2}M_{2}}{N_{1} + N_{2}}$$ $$SD = \sqrt{\frac{\left( {N_{1} - 1} \right)SD_{1}^{2} + \left( {N_{2} - 1} \right)SD_{2}^{2} + \frac{N_{1}N_{2}}{N_{1} + N_{2}}\left( {M_{1}^{2} + M_{2}^{2} - 2M_{1}M_{2}} \right)}{N_{1} + N_{2} - 1}}$$ where M and SD are the pooled mean and standard deviation of group 1 and group 2 (grouped by stage of HF). N~1~, M~1,~ and SD~1~ are the size, mean, and standard deviation of group 1, respectively; N~2,~ M~2,~ and SD~2~ are the size, mean, and standard deviation of group 2, respectively.

Data from included studies were combined and expressed as pooled weighted mean difference (WMD) with 95% CI. Studies were weighted by the inverse variance. A fixed-effects model was initially used in this meta-analysis. We evaluated heterogeneity across studies with Cochrane's Q test and I^2^ statistics. If *P* \< 0.10, statistically significant heterogeneity was considered to be present. The I^2^ statistic was used to quantify the magnitude of heterogeneity, with values of 0--25%, 25--50%, 50--75%, and \>75% representing mild, moderate, substantial heterogeneity, and considerable heterogeneity, respectively. We used influence analysis to drop a study whose point estimate lay outside the 95% CI of the summary analysis. All statistical analyses were performed using STATA software, V.12.0 (Stata Corp LP, College Station, Texas, USA).

Results {#sec011}
=======

Study flow diagram and baseline characteristics {#sec012}
-----------------------------------------------

Our literature search yielded 32 publications. Of these, 26 were excluded as they were duplications (n = 19), reviews (n = 3), comments (n = 2), irrelevant to the current analysis (n = 4), or compared only F4 with F0 (n = 3), or F0-2 with F3-4 (n = 1). Therefore, six studies met the inclusion and exclusion criteria to be enrolled in this study ([Fig 1](#pone.0147789.g001){ref-type="fig"}). The baseline characteristics of included studies and patients are shown in [Table 1](#pone.0147789.t001){ref-type="table"}. There were 406 patients included in these six studies (F0: 130 cases; F1: 55 cases; F2: 48 cases; F3: 55 cases; F4: 118 cases). All studies except two were performed in 2014 and 66.7% (4/6) were retrospective in nature. MRI scanners used included Siemens 1.5 T/3.0 T, GE 3.0 T and Philips 1.5T. Hepatic fibrosis, staged by METAVIR score (F0-F4), and confirmed by histopathology, was more common among adult men than among adult women.

![Flow diagram of included studies according to the inclusion and exclusion criteria.](pone.0147789.g001){#pone.0147789.g001}

10.1371/journal.pone.0147789.t001

###### The baseline characteristics of included studies and patients.

![](pone.0147789.t001){#pone.0147789.t001g}

  Study                                          Year   Study design    Sample size   Age                                         Male   MR scanner      Criteria of   TR/TE          b values                             Diagnosis of HF
  ---------------------------------------------- ------ --------------- ------------- ------------------------------------------- ------ --------------- ------------- -------------- ------------------------------------ ---------------------------------------
  Rom Chung *et al* \[[@pone.0147789.ref019]\]   2014   Retrospective   57            58.7 \*                                     61     Siemens 1.5T    METAVIR       60/2100        0, 30, 60, 100, 150, 200, 400, 600   histopathology, radiological findings
                                                                                                                                                                                      900                                  
  Ichikawa *et al* \[[@pone.0147789.ref031]\]    2014   Retrospective   182           66.4±11.6                                   69.8   GE 3.0 T        METAVIR       3000-4000/54   0, 10, 20, 30, 40, 50, 80, 100,      histopathology, MRI findings
                                                                                                                                                                                      200, 500, 1000                       
  Yoon *et al* \[[@pone.0147789.ref001]\]        2014   Retrospective   55            53.9[\*](#t001fn002){ref-type="table-fn"}   76     Siemens 3.0 T   METAVIR       5000/52        0, 25, 50, 75, 100, 200, 500, 800    histopathology, MRI findings
  Leporq *et al* \[[@pone.0147789.ref002]\]      2015   Retrospective   12            NA                                          NA     GE 3.0 T        METAVIR       2000/48        0, 20, 40, 60, 80, 100, 200, 300,    histopathology, MRI findings
                                                                                                                                                                                      400, 600, 800                        
  Lu *et al* \[[@pone.0147789.ref036]\]          2014   Prospective     51            37.3[\*](#t001fn002){ref-type="table-fn"}   67.6   Philips 1.5T    METAVIR       1500/63        10, 20, 40, 60, 80, 100, 150, 200,   histopathology, MRI findings
                                                                                                                                                                                      400, 800                             
  Wu *et al* \[[@pone.0147789.ref033]\]          2015   Prospective     49            62.4[\*](#t001fn002){ref-type="table-fn"}   73.5   Siemens 3.0 T   METAVIR       NA             0, 10, 20, 30, 40, 50, 60, 70, 80,   histopathology, MRI findings
                                                                                                                                                                                      90, 100, 200, 300, 400, 500, 1000    
  Wu *et al* \[[@pone.0147789.ref033]\]          2015   Prospective     49            62.4[\*](#t001fn002){ref-type="table-fn"}   73.5   Siemens 3.0 T   METAVIR       NA             0, 10, 20, 30, 40, 50, 60, 70, 80,   histopathology, MRI findings
                                                                                                                                                                                      90, 100, 200, 300, 400, 500, 1000    

*Note*: HF = hepatic fibrosis; NA = not available

\* mean value

Assessment of study quality and publication bias {#sec013}
------------------------------------------------

All studies included in this meta-analysis fulfilled nine or more of the 14 criteria in the QUADAS tool for methodological quality assessment. Common weaknesses were concentrated in criteria including 'description of pathology', 'interpretation of MRI blinded from reference' and 'interpretation of reference blinded from MRI'. The results of the quality assessment are presented in [Fig 2](#pone.0147789.g002){ref-type="fig"}. Since the number of included studies was less than 10 in all comparisons, the power of publication bias evaluation was very low; hence, it was not assessed and plotted.

![Assessment of quality of included studies using QUADAS tool.](pone.0147789.g002){#pone.0147789.g002}

IVIM-DWI for staging of hepatic fibrosis {#sec014}
----------------------------------------

We compared the parameters D, D\*, and *f* between different stages of HF, including F0 vs. F1 (normal vs. early stage), F0-1 vs. F2-3 (non-significant vs. significant stage), and F1-2 vs. F3-4 (non-advanced vs. advanced stage) ([Table 2](#pone.0147789.t002){ref-type="table"}):

10.1371/journal.pone.0147789.t002

###### Comparisions of different HF stages using IVIM-derived parameters and ADC value after pooled.

![](pone.0147789.t002){#pone.0147789.t002g}

  Stages         Study                                          Sample size   ADC (x 10^−3^ mm^2^/s)       D (x 10^−3^ mm^2^/s)         *f* (%)                         D\* (x 10^−3^ mm^2^/s)
  -------------- ---------------------------------------------- ------------- ---------------------------- ---------------------------- ------------------------------- --------------------------------
  F0 vs F1       Lu *et al* \[[@pone.0147789.ref036]\]          17 vs 14      NA                           1.096±0.155 vs 0.981±0.138   16.400±2.100 vs 14.500±2.800    13.085±2.943 vs 10.584±1.872
                 Ichikawa *et al* \[[@pone.0147789.ref031]\]    72 vs 13      1.190±0.140 vs 1.170±0.100   0.910±0.190 vs 0.900±0.150   24.600±7.280 vs 24.700±5.730    76.200±7.980 vs 75.700±10.300
                 Wu *et al* \[[@pone.0147789.ref033]\]          6 vs 16       0.920±0.110 vs 0.950±0.180   0.790±0.150 vs 0.780±0.260   33.860±9.460 vs 28.910±7.170    67.690±12.470 vs 57.160±19.020
  F0-1 vs F2-3   Ichikawa *et al* \[[@pone.0147789.ref031]\]    85 vs 33      1.187±0.135 vs 1.161±0.148   0.908±0.184 vs 0.853±0.143   24.615±7.035 vs 24.591±7.652    76.124±8.307 vs 63.500±10.915
                 Leporq *et al* \[[@pone.0147789.ref002]\]      7 vs 5        1.480±0.120 vs 1.340±0.170   1.110±0.120 vs 0.930±0.060   17.100±5.600 vs 22.700±10.100   92.300±18.000 vs 67.400±5.800
                 Yoon *et al* \[[@pone.0147789.ref029]\]        18 vs 16      1.230±0.170 vs 1.210±0.130   1.110±0.180 vs 1.100±0.150   30.800±4.950 vs 25.000±5.360    59.670±12.340 vs 41.780±15.830
                 Wu *et al* \[[@pone.0147789.ref033]\]          22 vs 20      0.942±0.162 vs 0.960±0.162   0.783±0.232 vs 0.885±0.212   30.260±7.945 vs 25.010±9.022    60.032±17.846 vs 49.570±17.074
  F1-2 vs F3-4   Rom Chung *et al* \[[@pone.0147789.ref019]\]   7 vs 29       1.170±0.114 vs 1.073±0.085   0.960±0.078 vs 0.938±0.081   33.800±6.000 vs 26.372±3.313    75.560±12.090 vs 64.232±8.630
                 Ichikawa *et al* \[[@pone.0147789.ref031]\]    27 vs 83      1.180±0.148 vs 1.125±0.127   0.884±0.169 vs 0.871±0.141   24.285±6.355 vs 22.401±6.776    71.344±12.319 vs 56.767±8.027
                 Lu *et al* \[[@pone.0147789.ref036]\]          22 vs 12      NA                           0.927±0.156 vs 0.898±0.152   13.556±2.673 vs 10.000±1.400    10.018±1.820 vs 8.332±0.851
                 Wu *et al* \[[@pone.0147789.ref033]\]          26 vs 17      0.935±0.185 vs 1.014±0.101   0.799±0.252 vs 0.969±0.171   27.672±7.520 vs 23.111±9.683    55.925±17.075 vs 38.721±18.518

*Note*: All values were expressed as mean ± standard deviation (SD); NA = not applicable; HF = hepatic fibrosis; IVIM = Intravoxel incoherent motion; ADC = apparent diffusion coefficient; D = pure molecular diffusion; *f* = perfusion fraction; D\* = pseudo-diffusion coefficient

**1) D\*.** As shown in [Fig 3](#pone.0147789.g003){ref-type="fig"}, results of forest plots showed statistically significant differences in D\* between F0 and F1 (WMD 2.46, 95% CI 0.83--4.09, *P* = 0.006; I^2^ = 0%, *P* = 0.413); between F0-1 and F2-3 (WMD 13.10, 95% CI 9.53--16.67, *P* \< 0.001; I^2^ = 0%, *P* = 0.537), and between F1-2 and F3-4 (WMD 14.34, 95% CI 10.26--18.42, *P* \< 0.001; I^2^ = 0%, *P* = 0.720). No significant heterogeneity was observed across studies.

![Comparing stage F0 with F1, F0-1 with F2-3, and F1-2 with F3-4 using D\*.\
We used influence analysis to drop a study exerted excessive influence on the overall estimate and therefore to decrease the heterogeneity. Abbreviations: WMD = weighted mean difference; CI = confidence interval.](pone.0147789.g003){#pone.0147789.g003}

**2) *f*.** As shown in [Fig 4](#pone.0147789.g004){ref-type="fig"}, significant differences in *f* were also found between F0 and F1 (WMD 1.62, 95% CI 0.06--3.18, *P* = 0.027; I^2^ = 0%, *P* = 0.446), between F0-1 and F2-3 (WMD 5.63, 95% CI 2.74--8.52, *P* \< 0.001; I^2^ = 0%, *P* = 0.863), and between F1-2 and F3-4 (WMD 3.30, 95% CI 2.10--4.50, *P* \< 0.001; I^2^ = 0%, *P* = 0.517). No significant heterogeneity was observed across studies.

![Comparing stage F0 with F1, F0-1 with F2-3, and F1-2 with F3-4 using *f*.\
We used influence analysis to drop a study exerted excessive influence on the overall estimate and therefore to decrease the heterogeneity. Abbreviations: WMD = weighted mean difference; CI = confidence interval.](pone.0147789.g004){#pone.0147789.g004}

**3) D.** As shown in [Fig 5](#pone.0147789.g005){ref-type="fig"}, no statistical difference in D was found in any comparison, including F0 vs. F1, F0-1 vs. F2-3, and F1-2 vs. F3-4 (WMD 0.05, 95% CI -0.01─0.11, *P* = 0.105; I^2^ = 18.0%, *P* = 0.295; WMD 0.04, 95% CI -0.01─0.10, *P* = 0.230; I^2^ = 0%, *P* = 0.489; WMD 0.02, 95% CI -0.02─0.06, *P* = 0.378; I^2^ = 0%, *P* = 0.967, respectively).

![Comparing stage F0 with F1, F0-1 with F2-3, and F1-2 with F3-4 using D.\
We used influence analysis to drop a study exerted excessive influence on the overall estimate and therefore to decrease the heterogeneity. Abbreviations: WMD = weighted mean difference; CI = confidence interval.](pone.0147789.g005){#pone.0147789.g005}

**4) ADC.** As shown in [Fig 6](#pone.0147789.g006){ref-type="fig"}, statistical difference in ADC existed between F1-2 and F3-4 (WMD 0.07, 95% CI 0.02--0.12, *P* = 0.002; I^2^ = 0%, *P* = 0.451). No statistical differences were found between F0 and F1 (WMD 0.01, 95% CI -0.05─0.07, *P* = 0.792; I^2^ = 0%, *P* = 0.483), and between F0-1 and F2-3 (WMD 0.02, 95% CI -0.02─0.07, *P* = 0.290; I^2^ = 0%, *P* = 0.488).

![Comparing stage F0 with F1, F0-1 with F2-3, and F1-2 with F3-4 using ADC.\
We used influence analysis to drop a study exerted excessive influence on the overall estimate and therefore to decrease the heterogeneity. Abbreviations: WMD = weighted mean difference; CI = confidence interval.](pone.0147789.g006){#pone.0147789.g006}

Discussion {#sec015}
==========

In this study, we found that IVIM MR can be used to distinguish liver in very early stages of HF from normal liver, significant HF from non-significant HF, and advanced HF from non-advanced HF. However, perfusion-related parameters (D\* and *f*) may be better suited to the detection of HF than the pure molecular diffusion parameter, D.

It is widely accepted that HF is associated with reduced hepatic perfusion; the increased arterial flow triggered by intrahepatic portal hypertension in HF is insufficient to compensate for the reduced portal flow \[[@pone.0147789.ref030]--[@pone.0147789.ref034]\]. In a study by Luciani et al., it was found that the mean portal flow in healthy subjects was 20.9 ± 4.1 mL/min/kg but decreased to 6.5 ± 5.6 mL/min/kg in patients with HF \[[@pone.0147789.ref030]\]. As a perfusion-related parameter, D\* may therefore potentially be a surrogate marker of hepatic perfusion \[[@pone.0147789.ref035]\]. And blood perfusion in chronic liver disease is an important marker for the staging of HF. In all included studies, D\* was significantly lower in patients with HF than in healthy subjects. Furthermore, the decrease in D\* in the liver was significantly associated with HF severity \[[@pone.0147789.ref036]\]. With the progression of HF, the accumulation of proteins in the extracellular matrix would gradually increase. Consequently, the mean values of D\* decrease as the fibrosis advances from F0 to F1, F0-1 to F2-3, and F1-2 to F3-4.

The parameter *f*, which represents blood volume, may not be a sensitive parameter compared with D\*, although significant differences in *f* were also observed between F0 and F1, F0-1 and F2-3, and F1-2 and F3-4 in this study. This is because blood volume of the hepatic is maintained by the arterial buffer response till HF becomes significant, while blood flow may decrease due to constricted sinusoidal space in early HF itself \[[@pone.0147789.ref001]\]. Moreover, *f* increased significantly with increasing echo time (TE) \[[@pone.0147789.ref037]\]. The TE-dependent variation in *f* is very important in tissues whose transverse relaxation time is remarkably shorter than that of blood, especially for organs with short T2 times like the liver \[[@pone.0147789.ref037]\]. After compensation for relaxation time, perfusion fraction *f* ' showed no significant dependence on TE \[[@pone.0147789.ref037]\]. The T2-attenuation is more obvious with a 3.0-T scanner than with a 1.5-T scanner \[[@pone.0147789.ref038]\]. Therefore, T2-compensation is needed more with a 3.0-T scanner. Regrettably, due to insufficient data, we could not perform a subgroup analysis by field strengths of MR scanners.

Interestingly, there were no significant differences in true molecular diffusion-related diffusion coefficient (D) between all compared stages of HF in our study. This may suggest that decreased D associated with advanced HF merely reflects decreased perfusion in micro-vessels rather than restricted molecular diffusion in the tissue \[[@pone.0147789.ref031]\]. Some study reported D values were previously found to be decreased significantly in severe liver fibrosis (stage F3 and stage F4), but had low correlations with fibrosis stage \[[@pone.0147789.ref001],[@pone.0147789.ref014],[@pone.0147789.ref023]\]. Some previous studies had reported no change in D values in patients with HF \[[@pone.0147789.ref030],[@pone.0147789.ref039]\], as indicated in this study.

It is generally recognized that DWI shows poor ability of detecting HF in the early stages (e.g. F1) when perfusion is not significantly altered. However, the lower ADC values in the advanced stages (F3-4) of HF are mainly due to decreased perfusion rather than decreased extravascular diffusion. Our results were in agreement with this; ADC could only be used to differentiate F3-4 from F1-2. It showed no statistical difference between F0 and F1. Hence, ADC may be not a sensitive marker for early HF. But it is controversial. some researchers \[[@pone.0147789.ref040]--[@pone.0147789.ref042]\] believe that due to the large amount of fibrous tissue in the extracellular space in liver fibrosis, the diffusion of water molecules is limited. Liver fibrosis accompanied by hepatocyte swelling and inflammatory cell infiltration can lead to decreased ADC values. Other researchers \[[@pone.0147789.ref013],[@pone.0147789.ref030],[@pone.0147789.ref043]\] have concluded that the ADC values decreased because of changes in the microcirculation due to proliferation of fibrous tissue. In addition, changes in fat and iron content in the liver also affect the ADC.

To our knowledge, this is the first meta-analysis determining the value of IVIM MR imaging in the diagnosis and staging of HF. However, this study has a few limitations. First, the sample size was small, only six studies were included, due to the limited sample size in this study, we did not evaluate the publication bias for this meta-analysis. Second, most of the studies were retrospective in nature. Third, we focused only on the three comparisons that are more clinically relevant, and did not compare other stages.

In summary, IVIM MR imaging provides a non-invasive alternative to liver biopsy for the staging of HF, with the added advantage that it does not require the intravenous injection of contrast media, which may induce adverse reactions, including contrast-induced acute kidney injury (CI-AKI). This technique can be used to distinguish very early HF from normal liver, significant HF from non-significant HF, and advanced HF from non-advanced HF. However, perfusion-related parameters (D\* and *f*) may be more suitable for this purpose than the pure molecular diffusion parameter (D). IVIM perfusion-related parameters may be superior to conventional ADC in the detection of early HF. Clinically, we can potentially use IVIM MR imaging to diagnose HF in the early stages and monitor the progression of HF in the future. Further research is warranted regarding the value of IVIM MR imaging in the diagnosis and staging of HF.
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